IMPORTANT INFORMATION FOR PATIENTS
Etravirine (Intelence®) is changing. The formulation has now changed from a 100mg tablet to a 200mg
tablet. This means you will only need to take two etravirine (Intelence®) 200mg tablets per day with your
other antiretrovirals.
From this
To this
Not actual size
Not actual size
Current dosage regimen of
4 x 100mg etravirine (Intelence®)
tablets per day
The new dosage regimen of
2 x 200mg etravirine (Intelence®)
tablets per day
Will this change the way etravirine (Intelence®) works?
No. The drug will work in exactly the same way.
Will there be any side effects when I switch?
You shouldn’t expect any new side effects when you start taking the new tablets, as they contain the same
drug. Occasionally some people may experience some minor side effects when they take a new formulation
of a drug, however these should settle. Speak to your doctor, pharmacist or nurse if you experience any
new side effects.
How do I switch to the new etravirine (Intelence®) 200mg tablet?
Once you have used up your current supply of etravirine (Intelence®) 100mg tablets you can switch to the
200mg tablets at your next scheduled dose.
If you take
etravirine
twice daily:
You will now
take ONE
200mg tablet
twice daily:
If you take
etravirine
once each
day:
You will now
take TWO
200mg
tablets once
each day
Please note that you if you are taking twice daily etravirine (Intelence®) you should not change the
frequency with which you take your antiretrovirals without discussing this with your doctor.
How do I take etravirine (Intelence®) 200mg tablets?
 Etravirine (Intelence®) should be swallowed whole with fluid and taken with or after food.
 The tablets can be dispersed in water if required, but please speak to your pharmacist about this.
The etravirine (Intelence®) 100mg tablet will continue to be available.
If you have any questions about etravirine (Intelence®) or any of your medicines please contact your
doctor or pharmacist on the number below:
Name:
Tel:
This leaflet was produced by the HIV pharmacy association (HIVPA). Version 2 (16/01/12). This leaflet does not replace the patient information leaflet
issued with the product, but should be read in conjunction with it. This leaflet should only be distributed to people already established on Intelence®
100mg tablets who are planning to switch to Intelence® 200mg tablets. This leaflet does not constitute any endorsement of the use of Intelence® by
HIVPA, and is intended for information purposes only. Intelence® at a dose of 400mg once each day is an unlicensed frequency, but is included within this
leaflet as it is used in clinical practice. Intelence® is a registered trade marks of Janssen. If you have any questions about this leaflet or Intelence®
please speak to your doctor, pharmacist or nurse.